Ascend Gene & Cell Therapies raises $65.9M from Petrichor Healthcare and Abingworth
05 May 2023
05 May 2023
Total investments received (USD): 65.9M
Round value (USD): 65.9M
Company: Ascend Gene & Cell Therapies
Related deals
Immutrin in a £65M series A led by Frazier Life Sciences, joined by SR One, Qiming Venture Partners, Cambridge Enterprise Ventures and F-Prime
Investments
07 March 2026
R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
Investments
01 March 2026
Chemify in a $50 million equity deal series B Extension backed by Zeon ventures from Japan
Investments
14 February 2026
Tenpoint Therapeutics raises $85M series B with Janus Henderson Investors, Hillhouse Investment, EQT and British Business Bank
Investments
30 January 2026
Beacon Tx raised $75m in Series C led by Goldman Sachs Alternatives, joined by the RD Fund, Syncona, Forbion, Oxford Science Enterprises, and Advent.
Investments
29 December 2025
Belgium
Austria
Germany
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal
Spain